Standout Papers
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial (2017)
Immediate Impact
1 by Nobel laureates 3 from Science/Nature 59 standout
Citing Papers
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
Works of Maria Taboada being referenced
Three-year overall survival update from the PACIFIC trial.
2019
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Maria Taboada | 511 | 507 | 61 | 100 | 16 | 837 | |
| C McAleer | 461 | 527 | 56 | 75 | 23 | 876 | |
| Anna-Larissa N. Niemeijer | 439 | 768 | 74 | 254 | 15 | 942 | |
| Donald Woytowitz | 390 | 471 | 32 | 141 | 19 | 718 | |
| Pamela Lockbaum | 220 | 758 | 53 | 92 | 13 | 973 | |
| Vishram B. Rege | 448 | 481 | 105 | 45 | 19 | 820 | |
| Sirisha L. Mushti | 303 | 677 | 91 | 210 | 16 | 892 | |
| P Chahinian | 486 | 480 | 60 | 47 | 31 | 821 | |
| James E. Bradof | 270 | 541 | 80 | 114 | 19 | 865 | |
| Kristina Lamberg | 412 | 402 | 59 | 45 | 20 | 762 | |
| Miriam Paone | 151 | 581 | 80 | 270 | 14 | 709 |
All Works
Loading papers...